Rybrevant Amivantamab EGFR MET Bispecific NSCLC Review 2026
Author: Critical Kare PharmaThoracic Oncology Desk
On October 15, 2026, thoracic oncology consortiums highlighted Rybrevant® (Amivantamab-vmjw 350 mg/7 mL vial) developed by Janssen as a practice-changing fully human EGFR-MET bispecific antibody for advanced NSCLC.
Rybrevant simultaneously engages extracellular domains of both EGFR and MET, blocking ligand binding, triggering receptor degradation, and recruiting immune effector cells via antibody-dependent cellular cytotoxicity (ADCC) across EGFR exon 20 insertions and classic EGFR-mutant disease.
Through Critical Kare Pharma, certified authentic packs of Rybrevant Amivantamab Solution for Infusion are supplied globally under GDP-certified 2°C–8°C cold-chain transport.
The PAPILLON & MARIPOSA Phase 3 Milestones
- PAPILLON Trial: Amivantamab plus chemotherapy significantly extended progression-free survival compared to chemotherapy alone in frontline EGFR exon 20 insertion NSCLC.
- MARIPOSA Trial: Demonstrated superior progression-free survival over osimertinib monotherapy in frontline classic EGFR-mutant (Exon 19 del / L858R) advanced NSCLC.
- Dosing: Weight-based: 1050 mg (<80 kg) or 1400 mg (≥80 kg) weekly for 4 weeks (with split Day 1/Day 2 infusion), followed by biweekly maintenance.
Global Procurement via Critical Kare Pharma
Accessible under official named-patient import regulations across the US, Europe, Middle East, and Asia-Pacific.
